These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32987253)

  • 1. Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Salvador-Coloma C; Santaballa A; Sanmartín E; Calvo D; García A; Hervás D; Cordón L; Quintas G; Ripoll F; Panadero J; Font de Mora J
    Eur J Cancer; 2020 Nov; 139():119-134. PubMed ID: 32987253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Guestini F; Ono K; Miyashita M; Ishida T; Ohuchi N; Nakagawa S; Hirakawa H; Tamaki K; Ohi Y; Rai Y; Sagara Y; Sasano H; McNamara KM
    Breast Cancer Res Treat; 2019 Jan; 173(2):275-288. PubMed ID: 30306430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    Wang RX; Chen S; Huang L; Shao ZM
    BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
    Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
    Wang Y; Brodsky AS; Xiong J; Lopresti ML; Yang D; Resnick MB
    Clin Breast Cancer; 2018 Jun; 18(3):e373-e379. PubMed ID: 28890185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study.
    Wang RX; Ji P; Gong Y; Shao ZM; Chen S
    Breast Cancer Res Treat; 2020 Jun; 181(3):561-570. PubMed ID: 32361849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
    Zhao Y; Wei L; Liu J; Li F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):77-93. PubMed ID: 31844921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Meyer B; Clifton S; Locke W; Luu PL; Du Q; Lam D; Armstrong NJ; Kumar B; Deng N; Harvey K; Swarbrick A; Ganju V; Clark SJ; Pidsley R; Stirzaker C
    Clin Epigenetics; 2021 Dec; 13(1):226. PubMed ID: 34922619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
    Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
    Bagegni NA; Tao Y; Ademuyiwa FO
    PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer.
    Kahraman M; Röske A; Laufer T; Fehlmann T; Backes C; Kern F; Kohlhaas J; Schrörs H; Saiz A; Zabler C; Ludwig N; Fasching PA; Strick R; Rübner M; Beckmann MW; Meese E; Keller A; Schrauder MG
    Sci Rep; 2018 Aug; 8(1):11584. PubMed ID: 30072748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
    Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.